Aveta Biomics, Inc.

Quick facts

Phase 2 pipeline

• APG-157 · Oncology
  APG-157 is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) analog.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Aveta Biomics, Inc. portfolio CI brief
• Aveta Biomics, Inc. pipeline updates RSS